Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company will conduct one-on-one investor meetings and a virtual fireside chat.
The chat is scheduled for 5:00-5:30 pm ET and will be presented by Ian Mortimer, the President and CEO. Attendees can access details and webcasts on the company’s website after the event.
Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +7.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
| Fireside Chat Details: | |
| Date: Time: Presenter: | Thursday, February 17, 2022 5:00-5:30 pm ET Ian Mortimer, President and CEO |
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.